Keishi Makino

Summary

Affiliation: Kumamoto University
Country: Japan

Publications

  1. request reprint
    Makino K, Kochi M, Nakamura H, Kuroda J, Honda Y, Ushio Y, et al. Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report. Neurol Med Chir (Tokyo). 2005;45:650-2 pubmed
    ..Colestimide probably interrupts the enterohepatic circulation, and is a potential oral antidote to MTX toxicity. ..
  2. Makino K, Nakamura H, Hide T, Kuratsu J. Risk of primary childhood brain tumors related to season of birth in Kumamoto Prefecture, Japan. Childs Nerv Syst. 2011;27:75-8 pubmed publisher
    ..Although our data provide modest support for a winter peak in the birth of children with brain tumors, we posit that there may be yet unknown, complex biological mechanisms that account for these putative seasonal patterns. ..
  3. Hayashi N, Takahashi H, Hasegawa Y, Higuchi F, Takahashi M, Makino K, et al. A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer. BMC Cancer. 2017;17:397 pubmed publisher
    ..Its use may help in determining an appropriate treatment for individual patients with BM. ..
  4. Makino K, Nakamura H, Hide T, Kuratsu J. Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status. J Neurooncol. 2012;106:155-60 pubmed publisher
    ..1 months) and nmMGMT (6.7 months) (P = 0.63). Although some patients were elderly and had been heavily pre-treated, temozolomide resulted in a complete response (CR) in 29% and was well tolerated without any major toxicity...